Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study was to determine if an idiotype vaccine, made from a patient's lymphoma that has returned after chemotherapy and/or rituximab, would be able to shrink their tumor.

Clinical Trial Description

The purpose of this study was to assess the ability of active immunotherapy to induce tumor regressions in relapsed low-grade lymphoma. B-cell malignancies express a unique antigen, the immunoglobulin idiotype (Id), on their surface. Each B-cell harbors a unique genetic sequence used in the production of immunoglobulin idiotype. B-cell lymphomas arise from the clonal expansion of a single B-cell and all tumor cells express that unique Id protein. No normal B-cells possess that Id on their cell surface. Hence, Id protein should serve as an ideal target for individualized active immune therapy of NHL. Many of the antigens expressed by tumors (including Id) are only weak immunogens. To augment the immune response against Id, the Id protein must be chemically coupled to a strongly immunogenic protein. Keyhole limpet hemocyanin (KLH) is a commonly used protein carrier capable of augmenting the body's immune reaction against Id protein. While initial studies reported a predominately humoral (antibody) response, cellular immunity (T-cells) also plays a critical role in anti-tumor immunity. GM-CSF is a hematopoietic growth factor that stimulates T-cell proliferation. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00036426
Study type	Interventional
Source	Favrille
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 2001

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00317096` - FCM Versus R-FCM Followed by R-Maintenance or Observation Only	Phase 3
Completed	`NCT00051025` - Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)	Phase 2
Not yet recruiting	`NCT03910283` - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer	N/A
Terminated	`NCT00143884` - Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood	Phase 2
Completed	`NCT00536458` - Treatment of Localized Low Grade Lymphomas	Phase 3
Withdrawn	`NCT01263418` - Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas	Phase 2
Completed	`NCT00168727` - Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma	Phase 4
Completed	`NCT00546793` - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL	Phase 1/Phase 2
Terminated	`NCT00060671` - Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma	Phase 3
Completed	`NCT00311129` - Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL	Phase 2
Completed	`NCT00060684` - Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma	Phase 1
Active, not recruiting	`NCT01181271` - Tandem Auto-Allo Transplant for Lymphoma	Phase 2
Completed	`NCT00220285` - Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma	Phase 2
Terminated	`NCT00038883` - Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies	N/A
Completed	`NCT00143845` - Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant	Phase 2